Abstract

BackgroundBy OMERACT, a core-set definition of minimal disease activity (MDA) required a tender joint count (TJC) of 0, swollen joint count (SJC) of 0, and erythrocyte sedimentation rate (ESR) ≤10...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
FRI0119 A proposal for a SDAI, CDAI, and RAPID3-based definition of minimal disease activity for use in routine care of rheumatoid arthritis: results from a japanese national database
S Sugii ... K Shimada
Annals of the Rheumatic Diseases | VOL. 76
S Sugii, et. al.S Sugii ... K Shimada
01 Jun 2017
AB0238 USEFULNESS OF RAPID3 IN ASSESSING UNMET NEEDS OF RHEUMATOID ARTHRITIS PATIENTS FROM THE T-FLAG STUDY
K Terabe ... R Sato
Annals of the Rheumatic Diseases | VOL. 82
K Terabe, et. al.K Terabe ... R Sato
30 May 2023
A Proposal to Standardize Low Disease Activity Criteria in Rheumatoid Arthritis Based on the Outcome Measures in Rheumatology Minimal Disease Activity Definition.
Akiko Komiya ... Shigeto Tohma
ACR open rheumatology | VOL. 2
Akiko Komiya, et. al.Akiko Komiya ... Shigeto Tohma
01 May 2020
Performance of routine assessment of patient index data 3 (RAPID3) in monitoring disease activity of Chinese rheumatoid arthritis patients.
Zhuoli Zhang ... Yanjie Hao
International journal of rheumatic diseases | VOL. 21
Zhuoli Zhang, et. al.Zhuoli Zhang ... Yanjie Hao
01 Nov 2018
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers